nodes	percent_of_prediction	percent_of_DWPC	metapath
Propranolol—SLC22A2—Neurotransmitter Clearance In The Synaptic Cleft—COMT—conduct disorder	0.0391	0.0412	CbGpPWpGaD
Propranolol—SLC22A2—Neurotransmitter Clearance In The Synaptic Cleft—MAOA—conduct disorder	0.0388	0.041	CbGpPWpGaD
Propranolol—HTR1B—Serotonin receptors—HTR2A—conduct disorder	0.0302	0.0319	CbGpPWpGaD
Propranolol—ADRB3—Monoamine GPCRs—DRD4—conduct disorder	0.0277	0.0292	CbGpPWpGaD
Propranolol—ADRB3—Amine ligand-binding receptors—DRD4—conduct disorder	0.0232	0.0245	CbGpPWpGaD
Propranolol—HTR1A—Serotonin receptors—HTR2A—conduct disorder	0.023	0.0243	CbGpPWpGaD
Propranolol—HTR1B—Monoamine GPCRs—DRD4—conduct disorder	0.0206	0.0217	CbGpPWpGaD
Propranolol—SLC22A2—Norepinephrine Neurotransmitter Release Cycle—MAOA—conduct disorder	0.0203	0.0214	CbGpPWpGaD
Propranolol—Duloxetine—SLC6A4—conduct disorder	0.0191	0.371	CrCbGaD
Propranolol—ADRB3—Monoamine GPCRs—HTR2A—conduct disorder	0.018	0.019	CbGpPWpGaD
Propranolol—HTR1B—Amine ligand-binding receptors—DRD4—conduct disorder	0.0173	0.0183	CbGpPWpGaD
Propranolol—ADRB3—G alpha (s) signalling events—CGA—conduct disorder	0.0171	0.0181	CbGpPWpGaD
Propranolol—ADRB1—Monoamine GPCRs—DRD4—conduct disorder	0.0164	0.0173	CbGpPWpGaD
Propranolol—ADRB2—Monoamine GPCRs—DRD4—conduct disorder	0.0161	0.0169	CbGpPWpGaD
Propranolol—HTR1A—Monoamine GPCRs—DRD4—conduct disorder	0.0157	0.0166	CbGpPWpGaD
Propranolol—ADRB3—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0152	0.016	CbGpPWpGaD
Propranolol—Duloxetine—HTR2A—conduct disorder	0.0147	0.285	CrCbGaD
Propranolol—ADRB1—Melatonin metabolism and effects—MAOA—conduct disorder	0.0146	0.0154	CbGpPWpGaD
Propranolol—CYP1A2—Methylation—COMT—conduct disorder	0.0143	0.015	CbGpPWpGaD
Propranolol—CYP1A1—Estrogen metabolism—COMT—conduct disorder	0.014	0.0147	CbGpPWpGaD
Propranolol—ADRB1—Amine ligand-binding receptors—DRD4—conduct disorder	0.0138	0.0145	CbGpPWpGaD
Propranolol—ADRB2—Amine ligand-binding receptors—DRD4—conduct disorder	0.0135	0.0142	CbGpPWpGaD
Propranolol—HTR1B—Monoamine GPCRs—HTR2A—conduct disorder	0.0134	0.0142	CbGpPWpGaD
Propranolol—HTR1A—Amine ligand-binding receptors—DRD4—conduct disorder	0.0132	0.0139	CbGpPWpGaD
Propranolol—HTR1B—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0113	0.0119	CbGpPWpGaD
Propranolol—ADRB1—Monoamine GPCRs—HTR2A—conduct disorder	0.0107	0.0113	CbGpPWpGaD
Propranolol—ADRB2—Monoamine GPCRs—HTR2A—conduct disorder	0.0105	0.011	CbGpPWpGaD
Propranolol—SLC22A2—Neurotransmitter Release Cycle—MAOA—conduct disorder	0.0103	0.0109	CbGpPWpGaD
Propranolol—HTR1A—Monoamine GPCRs—HTR2A—conduct disorder	0.0102	0.0108	CbGpPWpGaD
Propranolol—ADRB1—G alpha (s) signalling events—CGA—conduct disorder	0.0102	0.0107	CbGpPWpGaD
Propranolol—Atomoxetine—SLC6A4—conduct disorder	0.01	0.194	CrCbGaD
Propranolol—ADRB2—G alpha (s) signalling events—CGA—conduct disorder	0.00994	0.0105	CbGpPWpGaD
Propranolol—CYP1A1—Melatonin metabolism and effects—MAOA—conduct disorder	0.00948	0.01	CbGpPWpGaD
Propranolol—CYP1A1—Oxidative Stress—MAOA—conduct disorder	0.00923	0.00973	CbGpPWpGaD
Propranolol—ADRB1—Amine ligand-binding receptors—HTR2A—conduct disorder	0.009	0.00949	CbGpPWpGaD
Propranolol—CYP1A2—Estrogen metabolism—COMT—conduct disorder	0.00892	0.0094	CbGpPWpGaD
Propranolol—ADRB2—Amine ligand-binding receptors—HTR2A—conduct disorder	0.00881	0.00929	CbGpPWpGaD
Propranolol—HTR1A—Amine ligand-binding receptors—HTR2A—conduct disorder	0.00861	0.00908	CbGpPWpGaD
Propranolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00817	0.00861	CbGpPWpGaD
Propranolol—CYP2C19—Melatonin metabolism and effects—MAOA—conduct disorder	0.00776	0.00818	CbGpPWpGaD
Propranolol—Atomoxetine—HTR2A—conduct disorder	0.00771	0.149	CrCbGaD
Propranolol—CYP2D6—Melatonin metabolism and effects—MAOA—conduct disorder	0.00714	0.00753	CbGpPWpGaD
Propranolol—ADRB2—GPCRs, Other—DRD4—conduct disorder	0.00713	0.00752	CbGpPWpGaD
Propranolol—CYP3A4—Estrogen metabolism—COMT—conduct disorder	0.00688	0.00726	CbGpPWpGaD
Propranolol—CYP3A7—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00629	0.00663	CbGpPWpGaD
Propranolol—ADRB3—GPCR ligand binding—CGA—conduct disorder	0.00622	0.00656	CbGpPWpGaD
Propranolol—SLC22A2—Transmission across Chemical Synapses—GABRA2—conduct disorder	0.00619	0.00653	CbGpPWpGaD
Propranolol—HTR1B—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00609	0.00642	CbGpPWpGaD
Propranolol—CYP1A2—Melatonin metabolism and effects—MAOA—conduct disorder	0.00605	0.00638	CbGpPWpGaD
Propranolol—ADRB3—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00534	0.00563	CbGpPWpGaD
Propranolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00485	0.00511	CbGpPWpGaD
Propranolol—HTR1A—SIDS Susceptibility Pathways—SLC6A4—conduct disorder	0.00482	0.00508	CbGpPWpGaD
Propranolol—SLC22A2—Neuronal System—GABRA2—conduct disorder	0.00474	0.005	CbGpPWpGaD
Propranolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00474	0.005	CbGpPWpGaD
Propranolol—ADRB2—GPCRs, Other—HTR2A—conduct disorder	0.00465	0.00491	CbGpPWpGaD
Propranolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00464	0.00489	CbGpPWpGaD
Propranolol—HTR1B—GPCR ligand binding—CGA—conduct disorder	0.00463	0.00489	CbGpPWpGaD
Propranolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00457	0.00482	CbGpPWpGaD
Propranolol—CYP3A5—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00455	0.0048	CbGpPWpGaD
Propranolol—CYP1A1—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.0043	0.00453	CbGpPWpGaD
Propranolol—HTR1B—G alpha (i) signalling events—DRD4—conduct disorder	0.00429	0.00452	CbGpPWpGaD
Propranolol—HTR1B—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00398	0.00419	CbGpPWpGaD
Propranolol—ADRB1—GPCR ligand binding—CGA—conduct disorder	0.00369	0.00389	CbGpPWpGaD
Propranolol—HTR1A—SIDS Susceptibility Pathways—MAOA—conduct disorder	0.00363	0.00382	CbGpPWpGaD
Propranolol—ADRB2—GPCR ligand binding—CGA—conduct disorder	0.00361	0.00381	CbGpPWpGaD
Propranolol—HTR1A—GPCR ligand binding—CGA—conduct disorder	0.00353	0.00372	CbGpPWpGaD
Propranolol—CYP2C19—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00352	0.00371	CbGpPWpGaD
Propranolol—ADRB3—GPCR downstream signaling—CGA—conduct disorder	0.00351	0.00371	CbGpPWpGaD
Propranolol—ADRB3—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00348	0.00367	CbGpPWpGaD
Propranolol—ADRB3—GPCR ligand binding—DRD4—conduct disorder	0.00348	0.00367	CbGpPWpGaD
Propranolol—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00341	0.00359	CbGpPWpGaD
Propranolol—CYP3A7—Biological oxidations—COMT—conduct disorder	0.00337	0.00355	CbGpPWpGaD
Propranolol—CYP3A7—Biological oxidations—MAOA—conduct disorder	0.00334	0.00352	CbGpPWpGaD
Propranolol—CYP3A7—Metapathway biotransformation—COMT—conduct disorder	0.00332	0.0035	CbGpPWpGaD
Propranolol—HTR1A—G alpha (i) signalling events—DRD4—conduct disorder	0.00327	0.00344	CbGpPWpGaD
Propranolol—CYP2D6—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00323	0.00341	CbGpPWpGaD
Propranolol—ADRB3—Signaling by GPCR—CGA—conduct disorder	0.00319	0.00336	CbGpPWpGaD
Propranolol—ADRB1—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00317	0.00334	CbGpPWpGaD
Propranolol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.0031	0.00327	CbGpPWpGaD
Propranolol—HTR1A—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00303	0.00319	CbGpPWpGaD
Propranolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00298	0.00315	CbGpPWpGaD
Propranolol—SLC22A2—Transmission across Chemical Synapses—COMT—conduct disorder	0.00298	0.00314	CbGpPWpGaD
Propranolol—SLC22A2—Transmission across Chemical Synapses—MAOA—conduct disorder	0.00296	0.00312	CbGpPWpGaD
Propranolol—HTR1A—SIDS Susceptibility Pathways—HTR2A—conduct disorder	0.00296	0.00312	CbGpPWpGaD
Propranolol—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EP300—conduct disorder	0.00283	0.00299	CbGpPWpGaD
Propranolol—CYP1A1—Aryl Hydrocarbon Receptor—EP300—conduct disorder	0.00283	0.00299	CbGpPWpGaD
Propranolol—CYP1A2—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00274	0.00289	CbGpPWpGaD
Propranolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00271	0.00286	CbGpPWpGaD
Propranolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00265	0.0028	CbGpPWpGaD
Propranolol—HTR1B—GPCR downstream signaling—CGA—conduct disorder	0.00262	0.00276	CbGpPWpGaD
Propranolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.0026	0.00274	CbGpPWpGaD
Propranolol—HTR1B—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.0026	0.00274	CbGpPWpGaD
Propranolol—HTR1B—GPCR ligand binding—DRD4—conduct disorder	0.0026	0.00274	CbGpPWpGaD
Propranolol—SLC22A2—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.00255	0.00269	CbGpPWpGaD
Propranolol—CYP1A2—Phase II conjugation—COMT—conduct disorder	0.00251	0.00264	CbGpPWpGaD
Propranolol—CYP3A5—Biological oxidations—COMT—conduct disorder	0.00243	0.00257	CbGpPWpGaD
Propranolol—CYP3A5—Biological oxidations—MAOA—conduct disorder	0.00242	0.00255	CbGpPWpGaD
Propranolol—CYP3A5—Metapathway biotransformation—COMT—conduct disorder	0.0024	0.00253	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—CGA—conduct disorder	0.00238	0.00251	CbGpPWpGaD
Propranolol—CYP1A1—Biological oxidations—COMT—conduct disorder	0.0023	0.00242	CbGpPWpGaD
Propranolol—CYP1A1—Biological oxidations—MAOA—conduct disorder	0.00228	0.00241	CbGpPWpGaD
Propranolol—SLC22A2—Neuronal System—COMT—conduct disorder	0.00228	0.00241	CbGpPWpGaD
Propranolol—ADRB3—GPCR ligand binding—HTR2A—conduct disorder	0.00227	0.0024	CbGpPWpGaD
Propranolol—CYP1A1—Metapathway biotransformation—COMT—conduct disorder	0.00227	0.00239	CbGpPWpGaD
Propranolol—SLC22A2—Neuronal System—MAOA—conduct disorder	0.00227	0.00239	CbGpPWpGaD
Propranolol—HTR1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00222	0.00234	CbGpPWpGaD
Propranolol—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00211	0.00223	CbGpPWpGaD
Propranolol—ADRB1—GPCR downstream signaling—CGA—conduct disorder	0.00209	0.0022	CbGpPWpGaD
Propranolol—ADRB1—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00207	0.00218	CbGpPWpGaD
Propranolol—ADRB1—GPCR ligand binding—DRD4—conduct disorder	0.00207	0.00218	CbGpPWpGaD
Propranolol—ADRB2—GPCR downstream signaling—CGA—conduct disorder	0.00204	0.00215	CbGpPWpGaD
Propranolol—ADRB2—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00202	0.00213	CbGpPWpGaD
Propranolol—ADRB2—GPCR ligand binding—DRD4—conduct disorder	0.00202	0.00213	CbGpPWpGaD
Propranolol—HTR1A—GPCR downstream signaling—CGA—conduct disorder	0.00199	0.0021	CbGpPWpGaD
Propranolol—HTR1A—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00198	0.00208	CbGpPWpGaD
Propranolol—HTR1A—GPCR ligand binding—DRD4—conduct disorder	0.00198	0.00208	CbGpPWpGaD
Propranolol—ADRB3—GPCR downstream signaling—DRD4—conduct disorder	0.00197	0.00207	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.00196	0.00206	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—CGA—conduct disorder	0.00189	0.002	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—CGA—conduct disorder	0.00189	0.00199	CbGpPWpGaD
Propranolol—CYP2C19—Biological oxidations—COMT—conduct disorder	0.00188	0.00198	CbGpPWpGaD
Propranolol—CYP2C19—Biological oxidations—MAOA—conduct disorder	0.00187	0.00197	CbGpPWpGaD
Propranolol—CYP2C19—Metapathway biotransformation—COMT—conduct disorder	0.00186	0.00196	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—CGA—conduct disorder	0.00185	0.00195	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—CGA—conduct disorder	0.00181	0.00191	CbGpPWpGaD
Propranolol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—conduct disorder	0.00181	0.0019	CbGpPWpGaD
Propranolol—CYP1A2—Aryl Hydrocarbon Receptor—EP300—conduct disorder	0.00181	0.0019	CbGpPWpGaD
Propranolol—ADRB3—Signaling by GPCR—DRD4—conduct disorder	0.00179	0.00188	CbGpPWpGaD
Propranolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00177	0.00187	CbGpPWpGaD
Propranolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00173	0.00183	CbGpPWpGaD
Propranolol—CYP2D6—Biological oxidations—COMT—conduct disorder	0.00173	0.00182	CbGpPWpGaD
Propranolol—CYP2D6—Biological oxidations—MAOA—conduct disorder	0.00172	0.00181	CbGpPWpGaD
Propranolol—CYP2D6—Metapathway biotransformation—COMT—conduct disorder	0.00171	0.0018	CbGpPWpGaD
Propranolol—ABCB1—HIF-1-alpha transcription factor network—EP300—conduct disorder	0.00169	0.00179	CbGpPWpGaD
Propranolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00169	0.00179	CbGpPWpGaD
Propranolol—HTR1B—GPCR ligand binding—HTR2A—conduct disorder	0.00169	0.00179	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.0016	0.00169	CbGpPWpGaD
Propranolol—HTR1A—SIDS Susceptibility Pathways—EP300—conduct disorder	0.00157	0.00165	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—WASF1—conduct disorder	0.00151	0.00159	CbGpPWpGaD
Propranolol—HTR1B—GPCR downstream signaling—DRD4—conduct disorder	0.00147	0.00155	CbGpPWpGaD
Propranolol—CYP1A2—Biological oxidations—COMT—conduct disorder	0.00147	0.00155	CbGpPWpGaD
Propranolol—CYP1A2—Biological oxidations—MAOA—conduct disorder	0.00146	0.00153	CbGpPWpGaD
Propranolol—CYP1A2—Metapathway biotransformation—COMT—conduct disorder	0.00145	0.00152	CbGpPWpGaD
Propranolol—CYP1A1—PPARA activates gene expression—EP300—conduct disorder	0.00141	0.00149	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—CGA—conduct disorder	0.0014	0.00148	CbGpPWpGaD
Propranolol—ABCB1—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.00139	0.00147	CbGpPWpGaD
Propranolol—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—conduct disorder	0.00138	0.00145	CbGpPWpGaD
Propranolol—ADRB1—GPCR ligand binding—HTR2A—conduct disorder	0.00135	0.00142	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—DRD4—conduct disorder	0.00133	0.0014	CbGpPWpGaD
Propranolol—ADRB2—GPCR ligand binding—HTR2A—conduct disorder	0.00132	0.00139	CbGpPWpGaD
Propranolol—HTR1A—GPCR ligand binding—HTR2A—conduct disorder	0.00129	0.00136	CbGpPWpGaD
Propranolol—ADRB3—GPCR downstream signaling—HTR2A—conduct disorder	0.00128	0.00135	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—CGA—conduct disorder	0.00128	0.00134	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—CGA—conduct disorder	0.00127	0.00134	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.00125	0.00131	CbGpPWpGaD
Propranolol—ADRB1—GPCR downstream signaling—DRD4—conduct disorder	0.00117	0.00123	CbGpPWpGaD
Propranolol—ADRB3—Signaling by GPCR—HTR2A—conduct disorder	0.00117	0.00123	CbGpPWpGaD
Propranolol—ADRB2—GPCR downstream signaling—DRD4—conduct disorder	0.00114	0.0012	CbGpPWpGaD
Propranolol—CYP3A4—Biological oxidations—COMT—conduct disorder	0.00113	0.00119	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—WASF1—conduct disorder	0.00113	0.00119	CbGpPWpGaD
Propranolol—CYP3A4—Biological oxidations—MAOA—conduct disorder	0.00112	0.00118	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CGA—conduct disorder	0.00112	0.00118	CbGpPWpGaD
Propranolol—HTR1A—GPCR downstream signaling—DRD4—conduct disorder	0.00112	0.00118	CbGpPWpGaD
Propranolol—CYP3A4—Metapathway biotransformation—COMT—conduct disorder	0.00112	0.00118	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CGA—conduct disorder	0.00109	0.00115	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CGA—conduct disorder	0.00107	0.00113	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—DRD4—conduct disorder	0.00106	0.00112	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—DRD4—conduct disorder	0.00106	0.00111	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—DRD4—conduct disorder	0.00104	0.00109	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—DRD4—conduct disorder	0.00101	0.00107	CbGpPWpGaD
Propranolol—HTR1B—GPCR downstream signaling—HTR2A—conduct disorder	0.000957	0.00101	CbGpPWpGaD
Propranolol—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—conduct disorder	0.000951	0.001	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—CGA—conduct disorder	0.000922	0.000972	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—WASF1—conduct disorder	0.000897	0.000945	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—WASF1—conduct disorder	0.000877	0.000925	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—CGA—conduct disorder	0.000871	0.000918	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—HTR2A—conduct disorder	0.000869	0.000916	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—WASF1—conduct disorder	0.000858	0.000904	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—DRD4—conduct disorder	0.000787	0.00083	CbGpPWpGaD
Propranolol—ADRB1—GPCR downstream signaling—HTR2A—conduct disorder	0.000762	0.000804	CbGpPWpGaD
Propranolol—ADRB2—GPCR downstream signaling—HTR2A—conduct disorder	0.000745	0.000786	CbGpPWpGaD
Propranolol—HTR1A—GPCR downstream signaling—HTR2A—conduct disorder	0.000729	0.000769	CbGpPWpGaD
Propranolol—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—conduct disorder	0.000724	0.000763	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—CGA—conduct disorder	0.000713	0.000751	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—CGA—conduct disorder	0.000696	0.000733	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—HTR2A—conduct disorder	0.000692	0.00073	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—HTR2A—conduct disorder	0.000689	0.000726	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—HTR2A—conduct disorder	0.000677	0.000714	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—HTR2A—conduct disorder	0.000662	0.000698	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—CGA—conduct disorder	0.000655	0.000691	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—DRD4—conduct disorder	0.000627	0.000661	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—DRD4—conduct disorder	0.000613	0.000646	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—DRD4—conduct disorder	0.000599	0.000632	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—COMT—conduct disorder	0.000576	0.000607	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—COMT—conduct disorder	0.000575	0.000606	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—MAOA—conduct disorder	0.000572	0.000603	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—MAOA—conduct disorder	0.000571	0.000602	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—CGA—conduct disorder	0.000555	0.000586	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—HTR2A—conduct disorder	0.000513	0.000541	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—CGA—conduct disorder	0.000429	0.000452	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—COMT—conduct disorder	0.000416	0.000439	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—MAOA—conduct disorder	0.000413	0.000436	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—HTR2A—conduct disorder	0.000409	0.000431	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—HTR2A—conduct disorder	0.0004	0.000422	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—COMT—conduct disorder	0.000393	0.000415	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—HTR2A—conduct disorder	0.000391	0.000412	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—MAOA—conduct disorder	0.00039	0.000412	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.000379	0.000399	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—EP300—conduct disorder	0.000365	0.000385	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—COMT—conduct disorder	0.000322	0.000339	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—MAOA—conduct disorder	0.000319	0.000337	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—COMT—conduct disorder	0.000314	0.000331	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—MAOA—conduct disorder	0.000312	0.000329	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.00031	0.000327	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—COMT—conduct disorder	0.000296	0.000312	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—MAOA—conduct disorder	0.000294	0.00031	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—EP300—conduct disorder	0.000272	0.000287	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—COMT—conduct disorder	0.000251	0.000264	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—MAOA—conduct disorder	0.000249	0.000262	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—EP300—conduct disorder	0.000247	0.00026	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—EP300—conduct disorder	0.000246	0.00026	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.000241	0.000255	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—EP300—conduct disorder	0.000217	0.000228	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—EP300—conduct disorder	0.000212	0.000223	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—EP300—conduct disorder	0.000207	0.000218	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—COMT—conduct disorder	0.000193	0.000204	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—MAOA—conduct disorder	0.000192	0.000203	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—EP300—conduct disorder	0.000178	0.000188	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—EP300—conduct disorder	0.000169	0.000178	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—EP300—conduct disorder	0.000138	0.000145	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—EP300—conduct disorder	0.000135	0.000142	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—EP300—conduct disorder	0.000127	0.000134	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—EP300—conduct disorder	0.000107	0.000113	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—EP300—conduct disorder	8.3e-05	8.75e-05	CbGpPWpGaD
